Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Double Blind, Randomized, Placebo Controlled, Parallel Group, Trial to Explore the Potential Anti-dyskinetic Properties of CPL500036 (PDE10A Inhibitor) in Patients with Parkinson's Disease Suffering from Levodopa Induced Dyskinesia

NCT05297201 is registered in ClinicalTrials.gov with Celon Pharma SA as lead sponsor.

NCT NCT05297201
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05297201 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Double Blind, Randomized, Placebo Controlled, Parallel Group, Trial to Explore the Potential Anti-dyskinetic Properties of CPL500036 (PDE10A Inhibitor) in Patients with Parkinson's Disease Suffering from Levodopa Induced Dyskinesia
Lead sponsor
Celon Pharma SA
Phase
Phase 2
Overall status
Completed
Start date
November 2, 2021
Completion date
January 27, 2025
Enrollment
105 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

dyskinesia, medication-induced, parkinson disease